Cargando…

SARS-CoV-2 vaccine development, access, and equity

Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of...

Descripción completa

Detalles Bibliográficos
Autor principal: Kim, Jerome H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563686/
https://www.ncbi.nlm.nih.gov/pubmed/33064151
http://dx.doi.org/10.1084/jem.20201288
_version_ 1783595543063166976
author Kim, Jerome H.
author_facet Kim, Jerome H.
author_sort Kim, Jerome H.
collection PubMed
description Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of translating these approaches in other countries. An effective SARS-CoV-2 vaccine presents a technological solution to the failure of social and political ones. Vaccines are, however, not a silver bullet, but a safe, cost-effective, and globally applicable tool that will require a substantial effort—cooperation, commitment, time, and funding—to be effective.
format Online
Article
Text
id pubmed-7563686
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-75636862020-10-27 SARS-CoV-2 vaccine development, access, and equity Kim, Jerome H. J Exp Med Viewpoint Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of translating these approaches in other countries. An effective SARS-CoV-2 vaccine presents a technological solution to the failure of social and political ones. Vaccines are, however, not a silver bullet, but a safe, cost-effective, and globally applicable tool that will require a substantial effort—cooperation, commitment, time, and funding—to be effective. Rockefeller University Press 2020-10-16 /pmc/articles/PMC7563686/ /pubmed/33064151 http://dx.doi.org/10.1084/jem.20201288 Text en © 2020 Kim http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Viewpoint
Kim, Jerome H.
SARS-CoV-2 vaccine development, access, and equity
title SARS-CoV-2 vaccine development, access, and equity
title_full SARS-CoV-2 vaccine development, access, and equity
title_fullStr SARS-CoV-2 vaccine development, access, and equity
title_full_unstemmed SARS-CoV-2 vaccine development, access, and equity
title_short SARS-CoV-2 vaccine development, access, and equity
title_sort sars-cov-2 vaccine development, access, and equity
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563686/
https://www.ncbi.nlm.nih.gov/pubmed/33064151
http://dx.doi.org/10.1084/jem.20201288
work_keys_str_mv AT kimjeromeh sarscov2vaccinedevelopmentaccessandequity